StreetInsider.com News Articles

Celularity makes cell therapy available in Florida under new state law

Thu, 04 Jun 2026 08:03:07 -0400

Celularity Inc. (NASDAQ: CELU) announced the availability of cenplacel-L, a placental-derived cell therapy, for investigational use by licensed physicians in Florida under recently enacted state legislation. The company partnered with Fountain Life Management to provide the therapy through the new regulatory framework.

Florida Statutes § 458.3245 and § 459.0127, effective July 1, 2025, authorize licensed physicians to perform certain cell therapies not yet approved by the Food and Drug Administration, provided the treatments comply with sourcing, manufacturing, accreditation and patient consent requirements.

Cenplacel-L, also designated as PDA-001 or PDA-002 in clinical research, is manufactured at Celularity's FDA-registered, GMP-compliant facility. The therapy targets

Celularity makes cell therapy available in Florida under new state law

Thu, 04 Jun 2026 08:03:07 -0400

Cenplacel-L, also designated as PDA-001 or PDA-002 in clinical research, is manufactured at Celularity's FDA-registered, GMP-compliant facility. The therapy targets

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Thu, 04 Jun 2026 08:00:00 -0400

FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC (“Fountain Life”), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsible use of regenerative medicine.

This milestone marks the establishment of one of the

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Thu, 04 Jun 2026 08:00:00 -0400

This milestone marks the establishment of one of the

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Thu, 04 Jun 2026 08:00:00 -0400

This milestone marks the establishment of one of the

Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies

Thu, 04 Jun 2026 08:00:00 -0400

This milestone marks the establishment of one of the

Form 8-K Celularity Inc For: May 29

Wed, 03 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260603/26600374.html

Form 8-K Celularity Inc For: May 29

Wed, 03 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260603/26600374.html

Celularity names Rick Gonzalez as chief commercial officer

Wed, 03 Jun 2026 16:15:17 -0400

Celularity Inc. (NASDAQ: CELU) announced the appointment of Rick Gonzalez as chief commercial officer, according to a shareholder letter from Chief Executive Officer Robert Hariri.

The cellular medicine company completed a transaction with NexGel Inc. to out-license commercial assets of its biomaterials business for up to $30 million. The deal eliminated approximately $13 million in recorded liabilities and allows Celularity to focus on placental-derived cellular therapy programs.

Celularity is concentrating resources on cenplacel-L, a placental-derived allogeneic cell therapy developed from postpartum placental tissue. The company reports physician interest in the therapy and expects revenue growth in 2026 driven by increasing physician participation

Celularity Releases CEO Letter to Shareholders

Wed, 03 Jun 2026 16:15:00 -0400

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below.

Dear Fellow Shareholders,

I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context

Celularity Releases CEO Letter to Shareholders

Wed, 03 Jun 2026 16:15:00 -0400

Dear Fellow Shareholders,

I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context

Celularity names Rick Gonzalez as chief commercial officer

Wed, 03 Jun 2026 08:00:31 -0400

Celularity Inc. (NASDAQ: CELU) appointed Rick Gonzalez as chief commercial officer, effective May 29, 2026, according to a company statement. Gonzalez will oversee global commercial strategy for the company's cenplacel-L therapy, Lifebank cellular banking service, and broader regenerative medicine portfolio.

Gonzalez brings over 20 years of executive leadership experience in biotechnology and medical technology. He previously served as chief commercial officer at Alume Biosciences and as president and CEO of Navidea Biopharmaceuticals, where he led 2.5x year-over-year revenue growth. At Spectrum Pharmaceuticals, he helped scale global revenue from $7.7 million to approximately $300 million as senior vice president of global operations.

The

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Wed, 03 Jun 2026 08:00:00 -0400

Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank

FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company’s broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman,

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Wed, 03 Jun 2026 08:00:00 -0400

Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Wed, 03 Jun 2026 08:00:00 -0400

Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank

Celularity Appoints Rick Gonzalez as Chief Commercial Officer

Wed, 03 Jun 2026 08:00:00 -0400

Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Fri, 29 May 2026 17:15:00 -0400

FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all periodic financial reports with the U.S. Securities and

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Fri, 29 May 2026 17:15:00 -0400

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Fri, 29 May 2026 17:15:00 -0400

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Fri, 29 May 2026 17:15:00 -0400

Form 8-K Celularity Inc For: May 21

Thu, 28 May 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260528/26568606.html

Form 8-K Celularity Inc For: May 21

Thu, 28 May 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260528/26568606.html

Form NT 10-Q Celularity Inc For: Mar 31

Fri, 15 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260515/26506721.html

Form NT 10-Q Celularity Inc For: Mar 31

Fri, 15 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260515/26506721.html

Celularity regains NASDAQ compliance after filing delayed annual report

Fri, 01 May 2026 16:33:53 -0400

Celularity Inc. (NASDAQ: CELU) filed its Annual Report on Form 10-K for fiscal year 2025 and regained compliance with Nasdaq listing requirements, the company announced.

The regenerative medicine company received notification from Nasdaq on April 16 that it was not in compliance due to the delayed filing of its Form 10-K. After filing the report on April 30, Nasdaq notified Celularity on May 1 that it complies with Listing Rule 5250(c)(1) and the matter is closed.

The company has undertaken several restructuring initiatives, including out-licensing its biomaterials portfolio and reducing recorded liabilities by approximately $13 million. These actions resulted in personnel realignments